Related Experiment Video
Updated: Mar 6, 2026
12:02
Assays for the Identification of Novel Antivirals against Bluetongue Virus
Published on: October 11, 2013
14.6K
Identification of novel TACE inhibitors compatible with topical application
Gilles Ouvry1, Yaël Berton1, Yushma Bhurruth-Alcor1
1Nestlé Skin Health R&D, Les Templiers 2400 Route des Colles, 06410 Biot, France.
Bioorganic & Medicinal Chemistry Letters
|March 10, 2017
Summary
Researchers identified potent new inhibitors for Tumor Necrosis Factor Alpha Converting Enzyme (TACE) to treat psoriasis. Local TACE inhibition offers a promising therapeutic approach for mild to moderate psoriasis with potentially fewer side effects than systemic treatments.
Area of Science:
- Biochemistry
- Pharmacology
- Dermatology
Background:
- Tumor Necrosis Factor α (TNFα) signaling is a key target in psoriasis treatment.
- Current TNFα therapies involve antibodies, but local inhibition of TNFα Converting Enzyme (TACE, also known as ADAM17) offers a novel approach.
- Systemic TACE inhibition has side effects, necessitating development of localized treatments.
Purpose of the Study:
- To identify novel, potent inhibitors of TACE (ADAM17) for potential topical psoriasis therapy.
- To explore the structure-activity relationship (SAR) and ADME properties of new TACE inhibitors.
- To evaluate the potential of local TACE inhibition in treating mild to moderate psoriasis.
Main Methods:
- Enzymatic assays to determine inhibitor potency.
- Structure-Activity Relationship (SAR) studies.
- Absorption, Distribution, Metabolism, and Excretion (ADME) profiling.
- Physicochemical property analysis.
Main Results:
- Identification of potent enzymatic inhibitors of TACE.
- Detailed enzymatic SAR data were generated.
- ADME and physicochemical properties were assessed for the identified inhibitors.
- The study discusses suboptimal cellular activity in the context of existing literature.
Conclusions:
- Potent TACE inhibitors were successfully identified through enzymatic SAR and ADME studies.
- Local TACE inhibition presents a potential therapeutic strategy for psoriasis.
- Further optimization is needed to address cellular activity for clinical application.
